NCT02498756View on ClinicalTrials.gov

Cytokine-induced Killer Study for Patients With Stage II Melanoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2038

Study Completion Date

August 31, 2040

Conditions
Melanoma
Interventions
BIOLOGICAL

Cytokine-induced killer cells

CIK cells are transferred every 3 months for 1 year.

DRUG

Ipilimumab

Ipilimumab are delivered every 3 weeks for one year

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER

NCT02498756 - Cytokine-induced Killer Study for Patients With Stage II Melanoma | Biotech Hunter | Biotech Hunter